The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.